bosentan anhydrous has been researched along with iloprost in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 46 (54.76) | 29.6817 |
| 2010's | 35 (41.67) | 24.3611 |
| 2020's | 3 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bekjarova, A; Gatzke, R; Hoeper, MM; Spiekerkoetter, E; Taha, N | 1 |
| Barazzone-Argiroffo, C; Beghetti, M; Nicod, L; Rimensberger, PC | 1 |
| Hachulla, E | 1 |
| Alber, H; Colleselli, D; Kähler, CM; Molnar, C; Vogel, W | 1 |
| Widmar, B | 1 |
| Fruhwald, FM; Kjellström, B; Klein, W; Maier, R; Perthold, W; Wonisch, M | 1 |
| Ewert, R; Felix, S; Opitz, C; Schlag, K; Wensel, R | 1 |
| Agapito, AF; Cacela, D; Feliciano, J; Oliveira, JA; Quininha, J; Sousa, L | 1 |
| Halank, M; Hoeffken, G; Kolditz, M; Miehlke, S | 1 |
| Hammerschmidt, S; Pankau, H; Schauer, J; Seyfarth, HJ; Winkler, J; Wirtz, H | 1 |
| Halank, M; Hoeffken, G; Kolditz, M; Miehlke, S; Schiemanck, S; Schmeisser, A | 1 |
| Behr, J; Borst, MM; Ghofrani, A; Halank, M; Hoeper, M; Klose, H; Stähler, G; Wilkens, H; Winkler, J | 1 |
| Hoeper, MM; Markevych, I; Niedermeyer, J; Spiekerkoetter, E; Welte, T | 1 |
| Kayser, SR | 1 |
| Howard, LS; Morrell, NW | 1 |
| Ewert, R; Halank, M; Hoeffken, G; Kolditz, M; Opitz, C | 1 |
| Olschewski, H | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Arneson, C; Barst, RJ; Galie, N; Jeffs, R; Naeije, R; Rubin, LJ; Simonneau, G | 1 |
| Beghetti, M | 1 |
| Badesch, DB; Barst, RJ; Channick, RN; Frost, A; Hsu, HH; McLaughlin, VV; Murali, S; Oudiz, RJ; Rubin, LJ; Tapson, VF | 1 |
| Behr, J; Bremer, H; Halank, M; Hoeffken, G; Hoeper, MM; Kluge, S; Leuchte, H; Meyer, FJ; Ripken, F; Seyfarth, HJ; Wensel, R; Wilkens, H | 1 |
| Wilkens, H | 1 |
| Ghofrani, HA; Hoeper, MM | 1 |
| Hachulla, E; Humbert, M; Launay, D | 1 |
| Gabbay, E; Reed, A; Williams, TJ | 1 |
| Baloira, A | 1 |
| Fink, CA; Johnson, RF; Loyd, JE; Mullican, AL; Robbins, IM | 1 |
| García-Consuegra, J; González-Fernández, MA | 1 |
| Fain, O | 1 |
| Halank, M; Hoeffken, G; Hoeper, MM; Pletz, MW; Seyfarth, HJ; Spiekerkoetter, E; Welte, T; Wirtz, H | 1 |
| Dandel, M; Grauhan, O; Hetzer, R; Kemper, D; Knosalla, C; Lehmkuhl, HB; Mulahasanovic, S; Weng, Y | 1 |
| Humbert, M | 1 |
| Kawut, SM | 1 |
| Guillevin, L | 1 |
| Austin, MJ; Callender, ME; Heneghan, MA; Knisely, AS; McDougall, NI; O'Grady, JG; Rela, M; Sizer, E; Wendon, JA; Wilson, C | 1 |
| Park, MH | 1 |
| Antonelli-Incalzi, R; Catapano-Minotti, G; Corsonello, A; Guadalupi, G; Spani, R | 1 |
| Bouros, D; Steiropoulos, P; Trakada, G | 1 |
| Matucci-Cerinic, M; Seibold, JR | 1 |
| Ewert, R; Gläser, S; Opitz, CF; Schäper, C | 1 |
| Broomé, M; Frenckner, B; Lindström, M; Radell, P | 1 |
| Ahmad, S; Barnett, CF; Barnett, SD; Bonura, EJ; Girgis, RE; Hassoun, PM; Moller, DR; Nathan, SD; Osei, K; Shlobin, OA; Zaiman, AL | 1 |
| Li, D; Matuschak, GM; Nayak, RP | 1 |
| Barton, P; Chen, YF; Fry-Smith, A; Gibbs, JS; Hyde, C; Jowett, S; Malottki, K; Moore, D; Pepke-Zaba, J; Roberts, J | 1 |
| Achouh, L; Humbert, M; Jais, X; Launay, D; Le Pavec, J; Parent, F; Savale, L; Simonneau, G; Sitbon, O; Tchérakian, C; Yaïci, A | 1 |
| Levien, TL | 1 |
| Du, J; He, B; Jin, H; Li, X; Lin, G; Tang, C; Zhang, F | 1 |
| Weinerth, J; Wiesent, F | 1 |
| Akkoca Yıldız, O; Karabıyıkoğlu, G; Onen, ZP; Ozdemir Kumbasar, O; Sayın, T | 1 |
| Pope, J; Walker, KM | 1 |
| Bilici, M; Guzeltas, A; Odemis, E; Özyılmaz, İ; Tanidir, IC | 1 |
| Andreassen, AK; Gude, E; Solberg, OG; Ueland, T | 1 |
| Brodmann, M; Froehlich, H; Hafner, F; Steidl, K; Thomas, G | 1 |
| Celermajer, DS; Fowler, D; Garsia, R; Low, AJ; Manghani, MK; Torzillo, P; Young, I; Youssef, P | 1 |
| Hoeper, MM | 1 |
| Hoffmann, U; Kuhn, A; Riemekasten, G; Sunderkötter, C; Weiss, N | 1 |
| Huang, XM; Yu, YP | 1 |
| Sirmagul, B; Yigitaslan, S | 1 |
| Stern, PJ; Wall, LB | 1 |
| Cutolo, M; Pizzorni, C; Smith, V; Sulli, A; Vremis, L; Zampogna, G | 1 |
| Boutou, A; Kontou, P; Paspala, A; Pitsiou, G; Sourla, E; Stanopoulos, I | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Bölke, E; Buhren, BA; Gerber, PA; Hetzer, S; Homey, B; Kammers, K; Meller, S; Schrumpf, H | 1 |
| Cimmino, M; Cutolo, M; Paolino, S; Pizzorni, C; Ravera, F; Ruaro, B; Seriolo, B; Smith, V; Sulli, A; Zampogna, G | 1 |
| Cleary, KL; Običan, SG | 1 |
| Belz, D; Hunzelmann, N; Moinzadeh, P | 1 |
| Başer, HD; Cengel, A; Taçoy, G; Türkoğlu, S | 1 |
| Avcu, F; Doganci, S; Erol, G; Kadan, M; Ozgurtas, T; Ozkan, G; Yesildal, F; Yildirim, V | 1 |
| Kornacewicz-Jach, Z; Peregud-Pogorzelska, M | 1 |
| Bernal, M; De Cata, A; De Cosmo, S; Inglese, M; Mazzoccoli, G; Molinaro, F; Rubino, R | 1 |
| Etnel, J; Helbing, WA; Mank, A; Oldenburger, NJ; Takkenberg, JJ | 1 |
| Cannarile, F; Cestelli, V; Ferri, C; Giuggioli, D; Manfredi, A; Praino, E; Sebastiani, M | 1 |
| Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Smith, V; Sulli, A; Trombetta, AC | 1 |
| Chai, Y; Dong, L; Fang, L; Han, X; Li, S; Liu, L; Niu, M; Qu, S; Yang, X; Yu, Y; Zhang, Y | 1 |
| Blaise, S; Cracowski, JL; Forli, A; Imbert, B; Roustit, M | 1 |
| Cutolo, M; Paolino, S; Pizzorni, C; Ruaro, B; Sulli, A | 1 |
| Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA | 1 |
| Abignano, G; Allanore, Y; Avouac, J; Bellando-Randone, S; Blagojevic, J; Bruni, C; Cometi, L; Czirják, L; Del Galdo, F; Denton, CP; Distler, O; Frerix, M; Guiducci, S; Huscher, D; Jaeger, VK; Lóránd, V; Matucci-Cerinic, M; Maurer, B; Moggi-Pignone, A; Müller-Ladner, U; Nihtyanova, S; Riemekasten, G; Siegert, E; Tarner, IH; Vettori, S; Walker, UA | 1 |
| Jiang, X; Jing, ZC; Xu, XQ | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Dudek, K; Gajek, J; Jankowska-Polańska, B; Jonas, K; Kopeć, G; Sarzyńska, K; Świątoniowska-Lonc, N | 1 |
26 review(s) available for bosentan anhydrous and iloprost
| Article | Year |
|---|---|
[Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Calcium; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Scleroderma, Systemic; Sulfonamides | 2004 |
When cure is care: diagnosis and management of pulmonary arterial hypertension.
Topics: Adenosine; Algorithms; Antihypertensive Agents; Bosentan; Bronchodilator Agents; Calcium Channel Blockers; Decision Trees; Diagnosis, Differential; Epoprostenol; Fatal Outcome; Fenfluramine; Health Promotion; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Nitric Oxide; Nurse Practitioners; Primary Health Care; Prognosis; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sulfonamides; Vasodilator Agents | 2005 |
[Portopulmonary hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Epoprostenol; Hepatopulmonary Syndrome; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Lung; Pulmonary Wedge Pressure; Sulfonamides; Survival Rate; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2005 |
Combination drug therapy in the management of pulmonary arterial hypertension.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Cardiotonic Agents; Diuretics; Drug Monitoring; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prostaglandins; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2005 |
New therapeutic agents for pulmonary vascular disease.
Topics: Adult; Antihypertensive Agents; Arginine; Bosentan; Child; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Sulfonamides | 2005 |
[Diagnosis and treatment of pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Brain Infarction; Calcium Channel Blockers; Humans; Hypertension, Pulmonary; Iloprost; Life Expectancy; Pulmonary Heart Disease; Quality of Life; Sulfonamides | 2006 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Phosphodiesterase Inhibitors; Receptors, Endothelin; Sulfonamides; Vasodilator Agents | 2006 |
[Pulmonary arterial hypertension following pulmonary thromboembolism].
Topics: Antihypertensive Agents; Bosentan; Endarterectomy; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Pulmonary Embolism; Purines; Recurrence; Sildenafil Citrate; Splenectomy; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
[Drug combination treatment for pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2006 |
[Pulmonary arterial hypertension and systemic sclerosis].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cohort Studies; Echocardiography, Doppler; Epoprostenol; European Union; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Prognosis; Purines; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents; World Health Organization | 2006 |
Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006.
Topics: Adolescent; Adult; Aged; Arterioles; Australia; Bosentan; Cardiac Catheterization; Diagnostic Imaging; Disease Progression; Dyspnea; Endothelin A Receptor Antagonists; Epoprostenol; Exercise Test; Female; Forecasting; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Nitric Oxide; Piperazines; Prognosis; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Right | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
Current pharmacological treatment of pulmonary arterial hypertension.
Topics: Bosentan; Diuretics; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Nitric Oxide; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Digital ulcers and outcomes assessment in scleroderma.
Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Ischemia; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2008 |
[Combination therapy in patients with pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Prostaglandins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2008 |
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; United States; Vasodilator Agents | 2009 |
Advances in the treatment of Raynaud's phenomenon.
Topics: Antioxidants; Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Endothelin Receptor Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iloprost; Phosphodiesterase 5 Inhibitors; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulfonamides; Vasodilator Agents | 2010 |
Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2010 |
[Management of digital ulcers in patients with systemic sclerosis].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Ischemia; Male; Raynaud Disease; Risk Factors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2012 |
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides | 2012 |
Pulmonary arterial hypertension in pregnancy.
Topics: Anesthesia, Obstetrical; Bosentan; Carbolines; Directive Counseling; Epoprostenol; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Iloprost; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pregnancy, High-Risk; Prognosis; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
[Pregnant woman with pulmonary hypertension].
Topics: Antihypertensive Agents; Bosentan; Female; Humans; Hypertension, Pulmonary; Iloprost; Phosphodiesterase Inhibitors; Pregnancy; Pregnancy Complications; Sildenafil Citrate; Sulfonamides | 2015 |
Drug therapy in the prevention of failure of the Fontan circulation: a systematic review.
Topics: Bosentan; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Fontan Procedure; Heart Defects, Congenital; Hemodynamics; Humans; Iloprost; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Quality of life of patients with pulmonary arterial hypertension: a meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Humans; Iloprost; Pulmonary Arterial Hypertension; Quality of Life; Surveys and Questionnaires | 2021 |
12 trial(s) available for bosentan anhydrous and iloprost
| Article | Year |
|---|---|
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
Topics: Administration, Inhalation; Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Pilot Projects; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2003 |
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Epoprostenol; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Prospective Studies; Prostaglandins; Sulfonamides; Ultrasonography; Vasodilator Agents | 2005 |
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Topics: Administration, Inhalation; Algorithms; Antihypertensive Agents; Bosentan; Decision Support Systems, Clinical; Drug Administration Schedule; Drug Therapy, Combination; Female; Germany; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Cohort Studies; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Injections, Subcutaneous; Male; Middle Aged; Placebos; Sulfonamides; Survival Rate; Treatment Outcome | 2006 |
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Sulfonamides; Vasodilator Agents | 2006 |
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
Topics: Administration, Inhalation; Adult; Aged; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Sulfonamides; Vasodilator Agents | 2006 |
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Epidemiologic Methods; Epoprostenol; Exercise Test; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2010 |
Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.
Topics: Adult; Aged; Aged, 80 and over; Bosentan; Face; Female; Humans; Iloprost; Linear Models; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Sulfonamides; Telangiectasis | 2014 |
Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Laser-Doppler Flowmetry; Male; Microscopic Angioscopy; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents | 2014 |
Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Male; Pulmonary Artery; Quality of Life; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Walk Test | 2017 |
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey.
Topics: Adult; Bosentan; Calcium Channel Blockers; Drug Therapy, Combination; European Union; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Surveys and Questionnaires | 2019 |
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.
Topics: Adult; Aged; Bosentan; Drug Therapy, Combination; Europe; Female; Fingers; Humans; Iloprost; Male; Middle Aged; Prospective Studies; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Treatment Outcome; Vasodilator Agents; Wound Healing | 2020 |
46 other study(ies) available for bosentan anhydrous and iloprost
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
New combined treatments avoided transplantation in a child with severe pulmonary hypertension.
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Child; Drug Therapy, Combination; Echocardiography; Humans; Hypertension, Pulmonary; Iloprost; Male; Sulfonamides; Vasodilator Agents | 2004 |
Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Cirrhosis; Liver Transplantation; Middle Aged; Platelet Aggregation Inhibitors; Sulfonamides; Time Factors | 2004 |
Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
Topics: Administration, Inhalation; Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Monitoring, Ambulatory; Prostheses and Implants; Sulfonamides | 2005 |
[Pulmonary hypertension in hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease). Progression over 10 years].
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Diuretics; Endothelin Receptor Antagonists; Epistaxis; Epoprostenol; Female; Furosemide; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Nifedipine; Pedigree; Phenprocoumon; Pyridines; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic; Treatment Failure; Vasodilator Agents | 2005 |
Eisenmenger syndrome in the adult--experience with new drugs for the treatment of pulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Retrospective Studies; Sulfonamides; Vasodilator Agents | 2005 |
Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Liver Cirrhosis, Alcoholic; Male; Recurrence; Sulfonamides; Time Factors | 2005 |
[A role for combination therapy in pulmonary arterial hypertension].
Topics: Administration, Inhalation; Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Iloprost; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones | 2005 |
Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Middle Aged; Patient Selection; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2006 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiac Catheterization; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Male; Middle Aged; Piperazines; Purines; Retreatment; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents | 2007 |
Polyarteritis nodosa resistant to conventional treatment in a pediatric patient.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Arthralgia; Azathioprine; Bosentan; Child, Preschool; Cyclophosphamide; Female; Fever; Humans; Iloprost; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methylprednisolone; Polyarteritis Nodosa; Sulfonamides; Vasodilator Agents | 2007 |
[Digital necrosis in scleroderma].
Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Necrosis; Platelet Aggregation Inhibitors; Recurrence; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents | 2007 |
Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Bosentan; Catheterization; Disease-Free Survival; Female; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Sulfonamides; Treatment Outcome | 2007 |
Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Heart-Lung Transplantation; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Male; Middle Aged; Platelet Aggregation Inhibitors; Sulfonamides; Vasodilator Agents; Waiting Lists | 2007 |
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Phosphodiesterase Inhibitors; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Caring for the orphan's orphan: treatment of patients with portopulmonary hypertension.
Topics: Bosentan; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Patient Care; Sulfonamides; Survival Analysis | 2007 |
[Digital ulcers in systemic sclerosis].
Topics: Bosentan; Fingers; Humans; Iloprost; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2008 |
Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
Topics: Adult; Blood Pressure; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Diseases; Liver Transplantation; Male; Piperazines; Pulmonary Artery; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |
Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Topics: Bosentan; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Piperazines; Purines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2008 |
Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
Topics: Benzamides; Bosentan; Combined Modality Therapy; Continuous Positive Airway Pressure; Diuretics; Enteral Nutrition; Extracorporeal Membrane Oxygenation; Heart Failure; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Hypoxia; Iloprost; Imatinib Mesylate; Infant, Newborn; Male; Nitric Oxide; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.
Topics: Administration, Inhalation; Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Piperazines; Probability; Purines; Respiratory Function Tests; Retrospective Studies; Risk Assessment; Sarcoidosis; Severity of Illness Index; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Sulfones; Survival Rate; Treatment Outcome | 2009 |
Portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Echocardiography; Epoprostenol; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Transplantation; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
[Digital ulcers in systemic sclerosis--an interdisciplinary challenge].
Topics: Angiography; Antihypertensive Agents; Arm; Bosentan; Cooperative Behavior; CREST Syndrome; Endothelin Receptor Antagonists; Fatal Outcome; Fingers; Follow-Up Studies; Hand Dermatoses; Humans; Iloprost; Interdisciplinary Communication; Leg; Male; Middle Aged; Scleroderma, Limited; Skin Ulcer; Sulfonamides; Vasodilator Agents | 2010 |
[Efficacy of long-term oral monotherapy and additional effect of inhaled iloprost in patients with severe idiopathic pulmonary arterial hypertension].
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Hemodynamics; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides; Vasodilator Agents | 2010 |
Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.
Topics: Bosentan; Canada; Epoprostenol; Europe; Health Surveys; Humans; Hypertension, Pulmonary; Iloprost; Methotrexate; North America; Practice Guidelines as Topic; Scleroderma, Systemic; Skin Diseases; Societies, Medical; Sulfonamides; Treatment Outcome; Vascular Diseases | 2011 |
Transcatheter intervention following bosentan-iloprost treatment in a patient with patent ductus arteriosus and pulmonary hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Ductus Arteriosus, Patent; Female; Humans; Hypertension, Pulmonary; Iloprost; Septal Occluder Device; Sulfonamides; Vasodilator Agents | 2012 |
[Treatment of idiopathic pulmonary arterial hypertension].
Topics: Adult; Airway Resistance; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Lung Volume Measurements; Male; Middle Aged; Oxygen Consumption; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bosentan; Drug Therapy, Combination; Female; Fingers; Humans; Iloprost; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vasodilator Agents; Wound Healing; Young Adult | 2011 |
Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allergy and Immunology; Bosentan; Cardiac Catheterization; Cardiology; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Kaplan-Meier Estimate; Male; Mass Screening; Middle Aged; Outpatient Clinics, Hospital; Patient Care Team; Piperazines; Prospective Studies; Pulmonary Medicine; Purines; Rheumatology; Sildenafil Citrate; Sulfonamides; Sulfones; Tertiary Care Centers; Ultrasonography; Young Adult | 2013 |
"Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Female; Hypertension, Pulmonary; Iloprost; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2012 |
Nonoperative treatment of digital ischemia in systemic sclerosis.
Topics: Bosentan; Botulinum Toxins, Type A; Calcium Channel Blockers; Education, Medical, Continuing; Endothelin Receptor Antagonists; Evidence-Based Medicine; Female; Fingers; Humans; Iloprost; Ischemia; Life Style; Middle Aged; Orthopedics; Phosphodiesterase 5 Inhibitors; Prostaglandins; Randomized Controlled Trials as Topic; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Vascular Resistance; Vasodilator Agents | 2012 |
Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Iloprost; Male; Microscopic Angioscopy; Microvessels; Middle Aged; Nails; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2013 |
A case of pulmonary veno-occlusive disease: diagnostic dilemmas and therapeutic challenges.
Topics: Adult; Bosentan; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Humans; Iloprost; Lung; Lung Transplantation; Male; Piperazines; Pulmonary Artery; Pulmonary Veno-Occlusive Disease; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tomography, X-Ray Computed; Vasodilator Agents; Waiting Lists | 2013 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
[Digital ulcers in systemic scleroderma].
Topics: Bosentan; Fingers; Hand Dermatoses; Humans; Iloprost; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Wound Healing | 2014 |
[The management of adult female patients with Eisenmenger syndrome and advanced pulmonary arterial hypertension treatment: single center experience and follow-up for 5 years].
Topics: Adult; Antihypertensive Agents; Bosentan; Echocardiography; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Laser-Doppler Flowmetry; Piperazines; Pulmonary Wedge Pressure; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Turkey | 2014 |
Comparison of angiogenic and proliferative effects of three commonly used agents for pulmonary artery hypertension (sildenafil, iloprost, bosentan): is angiogenesis always beneficial?
Topics: Angiogenesis Inducing Agents; Animals; Bosentan; Cell Proliferation; Chick Embryo; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypertension, Pulmonary; Iloprost; Sildenafil Citrate; Sulfonamides | 2015 |
Digital ulcers in scleroderma patients: A retrospective observational study.
Topics: Adult; Bosentan; Female; Fingers; Humans; Iloprost; Leg; Male; Middle Aged; Retrospective Studies; Scleroderma, Localized; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2016 |
Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2017 |
Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Capillaries; Drug Therapy, Combination; Female; Fingers; Humans; Iloprost; Male; Microscopic Angioscopy; Middle Aged; Prospective Studies; Regional Blood Flow; Scleroderma, Systemic; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case.
Topics: Administration, Intravenous; Administration, Oral; Bosentan; Botulinum Toxins, Type A; Cross-Sectional Studies; Female; Fingers; Humans; Iloprost; Middle Aged; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Skin Ulcer; Sulfonamides; Treatment Outcome; Wound Healing | 2017 |
Assessment of treatment effects on digital ulcer and blood perfusion by laser speckle contrast analysis in a patient affected by systemic sclerosis.
Topics: Bosentan; Female; Fingers; Humans; Iloprost; Lasers; Methotrexate; Microcirculation; Microscopic Angioscopy; Middle Aged; para-Aminobenzoates; Raynaud Disease; Scattering, Radiation; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Tramadol; Treatment Outcome | 2017 |
The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS).
Topics: Academies and Institutes; Administration, Inhalation; Angioplasty, Balloon; Antihypertensive Agents; Asian People; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Cardiology; Cooperative Behavior; Endothelin Receptor Antagonists; Female; Growth Differentiation Factor 2; Guidelines as Topic; Humans; Iloprost; Mutation; Phenylpropionates; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pulmonary Medicine; Pyridazines; Takayasu Arteritis; Vasodilator Agents | 2019 |